Genetic analysis of benign ovarian tumors

International Journal of Cancer

Volumn 105, Issue 4, 2003, Pages 499-505

  Thomas, Nicola A ^a   Neville, Phillippa J ^b   Baxter, Simon W ^a   Campbell, Ian G ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b PRINCESS ANNE HOSPITAL   (United Kingdom)

Author keywords

Benign ovarian tumors; K ras; Loss of heterozygosity; Mutation analysis; TP53; Tumor suppressor genes

Indexed keywords

DNA; PROTEIN P53;

ARTICLE; BENIGN TUMOR; CHROMOSOME; DNA SEQUENCE; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE K RAS; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENES, P53; GENES, RAS; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0037936740     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11107     Document Type: Article

References (49)

1. Fearon ER, Vogelstein BA. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
2. Jiang X, Hitchcock A, Bryan EJ, Watson RH, Englefield P, Thomas EJ, Campbell IG. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 1996;56:3534-39.
3. Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell G. Allelo-typing of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998;58:1707-12.
4. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-7.
5. Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura Y. Allelotype of human ovarian cancer. Cancer Res 1991;51:5118-22.
6. Yang-Feng TL, Li S, Han H, Schwartz PE. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer 1992;52:575-80.
7. Leary JA, Doris CP, Boltz EM, Houghton CRS, Kefford R, Friedlander ML. Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer. Int J Gynecol Cancer 1993;3:293-8.
8. Osborne RJ, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 1994;69:429-38.
9. Gallion HH, PierettI M, DePries PD, van Nagell JRJ. The molecular basis of ovarian cancer. Cancer 1995;76:1992-7.
10. Shelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer 1995;25:521-7.
11. Saretzki G, Hoffmann U, Röhlke P, Psille R, Gaigal T, Keller G, Höfler H, Löning T, Petersen I, Dietel M. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 1997;80:1241-9.
12. Roy WJ, Watson RH, Hitchcock A, Campbell IG. Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours. Oncogene 1997;15:2031-5.
13. Mullenbach R, Lagoda PJ, Welter C. An efficient salt chloroform extraction of DNA from blood and tissues. Trends Genet 1989;5:391.
14. Zhang L, Cui XF, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome amplification from a single cell: implications for genetic-analysis. Proc Natl Acad Sci USA 1992;89:5847-51.
15. Beltinger CP, Klimek F and Debatin KM. Whole genome amplification of single cells from clinical peripheral blood smears. Mol Pathol 1997;50:272-5.
16. Neville PJ, Thomas N. Campbell IG. Loss of heterozygosity at 7q22 and mutation analysis of CDP gene in human epithelial ovarian tumours. Int J Cancer 2001;91:345-9.
17. Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan G, Boyer C, Jones K. Bast RC, Solomon E, Trowsdale J and Black DM. A novel gene encoding a B-Box protein within the BRCA1 region at 17q21.1. Human Mol Genet 1994;3:589-94.
18. Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, Blick M. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 1990;50:2724-8.
19. Zheng JP, Robinson WR, Ehlen T, Yu MC, Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res 1991;51:4045-51.
20. Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC, Jenkins RB. Human epithelial ovarian cancer allelotype. Cancer Res 1993;53:2393-8.
21. Weitzel JN, Patel J, Smith DM, Goodman A, Safaii H, Ball HG. Molecular genetic changes associated with ovarian cancer. Gynecol Oncol 1994;55:245-52.
22. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, Yang-Feng TL, Gray JW. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 1995;55:6172-80.
23. Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD and Campbell IG. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res 1996;56:719-21.
24. Link CJJ, Kohn E, Reed E. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. Gynecol Oncol 1996;60:347-54.
25. Chuaqui RF, Zhuang Z and Merino MJ. Molecular genetic events in the development and progression of ovarian cancer in humans. Mol Med Today 1997;3:207-13.
26. Yang-Chia S, Kerr JK, Hurst TG, Soo-Keat K, Ward BG, Chenevix-Trent G. No evidence for microsatellite instability from ovarian allelotype analysis of benign and low malignant potential ovarian neoplasms. Gynecol Oncol 1998;69:210-3.
27. Zborovskaya I, Gasparian A, Karseladze A, Elcheva I, Trofimova E, Driouch K, Trassard M, Tatosyan A, Lidereau R: Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity. Int J Cancer 1999;82:822-6.
28. Papp J, Csokay B, Bosze P, Zalay Z, Toth J, Ponder B, Olah E. Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas. Br J Cancer 1996;74:1592-7.
29. Campbell IG and Manolitsas T. Absence of PPP2R1B gene alterations in primary ovarian cancers. Oncogene 1999;18:6367-9.
30. Garcia A, Bussaglia E, Machin P, Matias-Guiu X, Prat J. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumours: association with carcinomas with serous differentiation. Int J Gynecol 2000;19:152-7.
31. Marks JR, Davidoff M, Kerns BJ, Humphrey PA, Pence JC, Dodge DK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
32. Naito M, Satake M, Sakai E, Hirano Y, Tsuchida N, Kanzaki H, Ito Y, Mori T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 1992;83:1030-6.
33. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarkepearson DL and Bast RC. Overexpression of p53 is not a feature of benign and early stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-6.
34. Imai S, Kiyozuka Y, Nishimura H, Iwanaga S, Murakami F, Imamura K, Noda T, Haga S, Yakushiji M. Overexpression of the tumor suppressor gene p53 in human ovarian tumor tissues and its correlation with clinical stage. Int J Oncol 1994;4:1097-1103.
35. Zheng J, Benedict WF, Xu HJ, Hu SX, Kim TM, Velicescu M, Wan M, Cofer K, Dubeau L. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 1995;87:1146-53.
36. Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Isao SW. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53:1489-92.
37. Fujita M, Enomoto T, Inoue M, Tanizawa O, Ozaki M, Rice JM, Nomura T. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 1994;85:1247-56.
38. Ichikawa Y, Nishida M, Suzuki H, Yoshida S, Tsunoda H, Kubo T, Uchida K, Miwa M. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994;54:33-5.
39. Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 1995;64:434-40.
40. Cuatrecasas M, Erill N, Musuln E, Ccosta I, Matais Guiu X, Prat J. K-ras mutations in non-mucinous ovarian epithelial tumours: a molecular analysis and clinicopathologic study of 144 patients. Cancer 1998;82:1088-95.
41. Mandai M, Konishi I, Kuroda H, Komatsu T, Yamamoto S, Nanbu K. Matsushita K, Fukumoto M, Yamabe H, Mori T. Heterogeneous distribution of K-ras mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Human Pathol 1998;29:34-40.
42. Suzuki M, Saito S, Saga Y, Ohwada M, Sato I. Mutation of K-ras protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas. Cancer Genet Cytogenet 2000;118:132-5.
43. Garret AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok, SC. K-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001;20:244-51.
44. Chenevix-Trench G, Kerr J, Hurst T, Shih YC, Purdie D, Bergman L, Friedlander M, Sanderson B, Zournazi A, Coombs T, Leary JA, Crawford E, et al. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chrom Cancer 1997;18:75-83.
45. Watson RH, Neville PJ, Roy WJ, Hitchcock A, Campbell IG. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis. Oncogene 1998;17:207-12.
46. Eccles DM, Russell SE, Haites E, Atkinson R, Bell DW, Gruber L, Hickey I, Kelly K, Kitchener H, Leonard R. Early loss of heterozygosity on 17q in ovarian cancer: The Abe Ovarian Cancer Genetics Group. Oncogene 1992;7:2069-72.
47. Foulkes WD, Black DM, Stamp GW, Solomon E, Trowsdale J. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 1993;54:220-5.
48. Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP, Donis-Keller H. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 1996;56:606-11.
49. Dion F, Mes-Masson AM, Seymour RJ, Provencher D, Tonin PN. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 2000;19:1466-72.